Form 4: Pliant Therapeutics Executive Mike Ouimette Reports Stock and Option Awards

Pliant Therapeutics' General Counsel and Corporate Secretary, Mike Ouimette, received 35,000 shares of common stock and options to purchase 70,000 shares, according to a recent SEC filing.

Summary

• Mike Ouimette, General Counsel and Corporate Secretary of Pliant Therapeutics, Inc., reported a transaction involving the acquisition of company stock and stock options.
• On January 23, 2025, Mr. Ouimette acquired 35,000 shares of common stock, which were granted as restricted stock units.
• These restricted stock units vest in three equal annual installments starting January 16, 2025, contingent on his continued employment with the company.
• Additionally, Mr. Ouimette received options to purchase 70,000 shares of common stock at an exercise price of $11.14 per share.
• These options vest monthly over four years, starting January 1, 2025, also subject to his continued service with the company.
• Following these transactions, Mr. Ouimette directly owns 105,544 shares of common stock and options to purchase 70,000 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns executive interests with shareholder value. The sentiment is neutral to positive.

Positives

• The grant of stock and options to a key executive like the General Counsel and Corporate Secretary can be seen as a positive incentive for continued service and alignment with shareholder interests.
• The vesting schedules for both the stock and options encourage long-term commitment from Mr. Ouimette.

Risks

• The vesting of the stock and options is contingent on Mr. Ouimette's continued employment, which introduces a risk of forfeiture if he leaves the company before the vesting dates.
• The value of the options is dependent on the future performance of the company's stock price, which is subject to market risks.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This type of stock and option grant is a common practice in the biotechnology industry to incentivize and retain key executives. It aligns the executive's interests with those of the shareholders by tying compensation to the company's performance.

Comparison to Industry Standards

• Stock option grants and restricted stock units are standard compensation practices for executives in the biotechnology sector.
• Companies like BioMarin Pharmaceutical Inc. and Vertex Pharmaceuticals Incorporated also use similar equity-based compensation to attract and retain talent.
• The vesting schedules described are typical, with multi-year vesting periods to encourage long-term commitment.
• The specific amounts of stock and options granted are dependent on the executive's role and the company's overall compensation strategy, and would need to be compared to similar roles at comparable companies to assess if they are in line with industry standards.

Stakeholder Impact

• Shareholders may view the stock and option grants as a positive sign of management's commitment to the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership team.
• The grants do not have a direct impact on customers, suppliers, or creditors.

Key Dates

Keywords

stock options, restricted stock units, insider trading, executive compensation, beneficial ownership, Pliant Therapeutics, PLRX